Acetylcholine signaling through muscarinic receptors has been shown to benefit memory performance in some conditions, but pan-muscarinic activation also frequently leads to peripheral side effects. Drug therapies that selectively target M1 or M4 muscarinic receptors could potentially improve memory while minimizing side effects mediated by the other muscarinic receptor subtypes. The ability of three recently developed drugs that selectively activate M1 or M4 receptors to improve recognition memory was tested by giving Long-Evans rats subcutaneous injections of three different doses of the M1 agonist VU0364572, the M1 positive allosteric modulator BQCA or the M4 positive allosteric modulator VU0152100 before performing an object recognition memory task. VU0364572 at 0.1 mg/kg, BQCA at 1.0 mg/kg and VU0152100 at 3.0 and 30.0 mg/kg improved the memory performance of rats that performed poorly at baseline, yet the improvements in memory performance were the most statistically robust for VU0152100 at 3.0 mg/kg. The results suggested that selective M1 and M4 receptor activation each improved memory but that the likelihood of obtaining behavioral efficacy at a given dose might vary between subjects even in healthy groups depending on baseline performance. These results also highlighted the potential of drug therapies that selectively target M1 or M4 receptors to improve memory performance in individuals with impaired memory.

Keywords:
Acetylcholine receptor, Muscarinic receptor, Memory, Alzheimer’s disease, Schizophrenia
1.
Deutsch JA, Rocklin KW: Amnesia induced by scopolamine and its temporal variations. Nature 1967;269:89-90.
2.
Bubser M, Byun N, Wood MR, Jones CK: Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol 2012;208:121-166.
3.
Levey AI: Immunological localization of M1-M5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993;52:441-448.
4.
Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR: Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991;11:3218-3226.
5.
Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, et al: Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci 2003;17:1403-1410.
6.
Conn PJ, Christopoulos A, Lindsley CW: Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54.
7.
Conn PJ, Jones CK, Lindsley CW: Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2010;30:148-155.
8.
Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, et al: Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 2008;327:941-953.
9.
Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, et al: Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J Neurosci 2012;32:8532-8544.
10.
Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, et al: Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett 2011;21:6451-6455.
11.
Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, et al: A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 2009;29:14271-14286.
12.
Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, et al: Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci 2009;106:15950-15955.
13.
Araujo JA, Greig NH, Ingram DK, Sandin J, de Rivera C, Milgram NW: Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. J Alzheimers Dis 2011;26:143-155.
14.
Chuah LY, Chong DL, Chen AK, Rekshan WR 3rd, Tan JC, Zheng H, Chee MW: Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep 2009;32:999-1010.
15.
Malkova L, Kozikowski AP, Gale K: The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques. Neuropharmacology 2011;60:1262-1268.
16.
Raffaele KC, Berardi A, Morris PP, Asthana S, Haxby JV, Schapiro MB, et al: Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:643-648.
17.
Cui YH, Si W, Yin L, An SM, Jin J, Deng SN, Cao XH: A novel derivative of xanomeline improved memory function in aged mice. Neurosci Bull 2008;24:251-257.
18.
Ennaceur A, Delacour J: A new one-trial test for neurobiological studies of memory in rats. 1. Behavioral data. Behav Brain Res 1988;31:47-59.
19.
Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, et al: Chemical modification of the M1 agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. ACS Chem Neurosci 2012;3:1025-1036.
20.
Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, et al: An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 2008;4:42-50.
21.
Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, et al: Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system. ACS Chem Neurosci 2010;1:104-121.
22.
Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, et al: Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 2010;78:1105-1123.
23.
Clark RE, Squire LR: An animal model of recognition memory and medial temporal lobe amnesia: history and current issues. Neuropsychologia 2010;48:2234-2244.
24.
Bass DI, Partain KN, Manns JR: Event-specific enhancement of memory via brief electrical stimulation to the basolateral complex of the amygdala in rats. Behav Neurosci 2012;126:204-208.
25.
Trimper JB, Stefanescu RA, Manns JR: Recognition memory and theta-gamma interactions in the hippocampus. Hippocampus, Epub ahead of print.
26.
Nesselroade JR, Stigler SM, Baltes PB: Regression toward the mean and the study of change. Psychol Bull 1980;88:622-637.
27.
Barnett AG, van der Pols JC, Dobson AJ: Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005;34:215-220.
28.
Kimura F, Baughman RW: Distinct muscarinic receptor subtypes suppress excitatory and inhibitory synaptic responses in cortical neurons. J Neurophysiol 1997;77:709-716.
29.
Rahman J, Berger T: Persistent activity in layer 5 pyramidal neurons following cholinergic activation of mouse primary cortices. Eur J Neurosci 2011;34:22-30.
30.
Wilson DA: Scopolamine enhances generalization between odor representations in rat olfactory cortex. Learn Mem 2001;8:279-285.
31.
Chen KC, Baxter MG, Rodefer JS: Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur J Neurosci 2004;20:1081-1088.
32.
Schmidt LS, Thomsen M, Weikop P, Dencker D, Wess J, Woldbye DP, Wörtwein G, Fink-Jensen A: Increased self-administration in M4 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berlin) 2011;216:367-378.
33.
Hasselmo ME, McGaughy J: High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res 2004;145:207-231.
34.
Jutras MJ, Buffalo EA: Recognition memory signals in the macaque hippocampus. Proc Natl Acad Sci USA 2010;107:401-406.
35.
Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ: Expression of M1-M4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 1995;15:4077-4092.
36.
Mulugeta E, Chandranath I, Karlsson E, Winblad B, Adem A: Temporal and region-dependent changes in muscarinic M4 receptors in the hippocampus and entorhinal cortex of adrenalectomized rats. Exp Brain Res 2006;173:309-317.
37.
Parron C, Save E: Comparison of the effects of entorhinal and retrosplenial cortical lesions on habituation, reaction to spatial and non-spatial changes during object exploration in the rat. Neurobiol Learn Mem 2004;82:1-11.
38.
Tang Y, Mishkin M, Aigner TG: Effects of muscarinic blockade in perirhinal cortex during visual recognition. Proc Natl Acad Sci 1997;94:12667-12669.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.